Trial reportNature communications2022
A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03827837 (Famitinib Malate Plus Anti-PD1 Therapy), which is not on this map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Efficacy and safety of combined immune therapy for advanced cervical cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.Frontiers in immunology · 2024Pooled it
- Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer.BMC medicine · 2025Trial
- First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.Journal for immunotherapy of cancer · 2024Trial
- Efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced cervical cancer: A systematic review and meta-analysis.Oncology letters · 2026Article
- Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.Communications medicine · 2026Article
- Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them.Frontiers in immunology · 2026Review
- Review
- The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review.Translational lung cancer research · 2025Review
- Dynamic changes in peripheral blood immunophenotyping and its prognostic value in cervical cancer patients undergoing immune checkpoint blockade therapy.Discover oncology · 2025Article
- Advances in cervical cancer: current insights and future directions.Cancer communications (London, England) · 2025Review
- Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study.Innovation (Cambridge (Mass.)) · 2025Article
- Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial.Therapeutic advances in medical oncology · 2025Article
- Novel combination of immunotherapy and tyrosine kinase inhibitor for recurrent cervical cancer: balancing efficacy and toxicity.Gynecology and pelvic medicine · 2025Article
- Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis.Frontiers in oncology · 2024Article
- Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy.Frontiers in oncology · 2024Review
- Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.Current oncology reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squamous cell carcinoma experiencing relapse or progression during or after 1-2 lines of systemic therapy for recurrent or metastatic disease are enrolled. Eligible patients receive camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily. The primary endpoint is the objective response rate. Secondary endpoints are duration of response, disease control rate, time to response, progression-free survival, overall survival, and safety. The trial has met pre-specified endpoint. Thirty-three patients are enrolled; median follow-up lasts for 13.6 months (interquartile range: 10.0-23.6). Objective responses are observed in 13 (39.4%, 95% confidence interval [CI]: 22.9-57.9) patients; the 12-month duration of response rate is 74.1% (95% CI: 39.1-90.9). Median progression-free survival is 10.3 months (95% CI: 3.5-not reached) and the 12-month overall survival rate is 77.7% (95% CI: 58.9-88.7). All patients experience treatment-related adverse events; grade ≥3 events occur in 26 (78.8%) patients. Treatment-related serious adverse events and deaths are observed in 9 (27.3%) and 2 (6.1%) patients, respectively. Camrelizumab plus famitinib shows promising antitumor activity with a manageable and tolerable safety profile in patients with pretreated recurrent or metastatic cervical squamous cell carcinoma. This combination may represent a treatment option for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.